Docteur Oswald VAN CUTSEM Pneumologue Chef de Service Contacts secrétariat planning : 081. 20 96 61 secrétariat consultations : 081. 20 94 61 Diplômes : Doctorat UCL 1983 Diplôme de spécialiste en pneumologie UCL 1988 Mandats Membre de l European Lung Cancer Working Party Membre de la Société Belge de Pneumologie Membre de la Société de Pathologie Thoracique du Nord (France) Membre de la Société de Pneumologie de langue française Membre de l European Respiratory Society Publications VAN CUTSEM O., REMY J., WALLAERT B., TONNEL A.B. Fièvre, douleur et cavité. Rev. Mal. Resp. 1988, 5, 81-83
VAN CUTSEM O., MERRILL W.W. Aerobic gram positive infections Current Therapy Disease B.C. Deckers Inc. Toronto. Philadelphia R.M. Cherniak, 372 pages - 189 VAN CUTSEM O.,, LEDENT C., MAIRESSE M. Le granulome hyalinisant du poumon. Rev. Mal. Resp. 1990, 7, 279-282 SCULIER J.-P., PAESMANS M., BUREAU G., DABOUIS G., LIBERT P., VANDERMOTEN G., VAN CUTSEM O., BERCHIER M.-C., RIES F., MICHEL J., SERGYSELS R., MOMMEN P., KLASTERSKY J. Une chimiothérapie hebdomadaire avec de multiples médicaments ou un traitement de chimiothérapie standard : résultats d une étude phase III conduite dans le cancer bronchique à petites cellules par l European Lung Cancer Working Rev. Mal. Resp. 1994, 11 : 257-261 KLASTERSKY J., SCULIER J.-P., RIES F., DABOUIS G., LIBERT P., SCHMERBER J., THIRIAUX J., BERCHIER M.-C., BUREAU G., VAN CUTSEM O., TAGNON A., SERGYSELS R., MOMMEN P., PAESMANS M. for the European Lung Cancer Working party. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5- fluorouracil. Annals of Oncology 1994, 5 : 641-643. SCULIER J.-P., PAESMANS M., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J., VAN CUTSEM O., SCHMERBER J., GINER V., VERCHIER M.-C., SERGYSELS R., MOMMEN P., KLASTERSKY J. for the European Lung Cancer Working party. Long-term survival after chemotherapy containing platinum derivatives in patient with advanced unresectable non small cell lung cancer. Eur. J. Cancer. 1994, 30A : 1342-1347. KLASTERSKY J., SCULIER J.-P., RIES F., DABOUIS G., LIBERT P., SCHMERBER J., THIRIAUX J., BERCHIER M.-C., BUREAU G., VAN CUTSEM O., TAGNON A., SERGYSELS R., MOMMEN P., PAESMANS M. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile : a regimen associated with majour toxicity in patients with advance non-small cell lung cancer. SCULIER J.-P., BUREAU G., GINER V., THIRIAUX J., MICHEL J., BERCHIER M.-C., VAN CUTSEM O., KÜSTNER U., KROLL F., MOMMEN P., PAESMANS M., KLASTERSKY J. Induction chemotherapy with ifosfamide, etoposide, ans anthracycline for small cell lung. Experience of the European Lung Cancer Working Sem. Oncol. 1995 22 (suppl.2) : 18-22.
PAESMANS M., SCULIER J.-P., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J., VAN CUTSEM O., SERGYSELS R., MOMMEN P., KLASTERSKY for the European Lung Cancer Working party. Prognostic factors for survival in advance non small cell lung cancer ; uni-and multivariate analyses including recpam analysis in 1052 patients. J. Clin. Oncol 1995 13 : 1221-1230 Update pour Classic Papers and Current Comments : 1997, 2 (1) : 124-134 (Highlights of lung cancer research). SCULIER J.-P., PAESMANS M., BUREAU G., GINER V., LECOMPTE J., MICHEL J., BERCHIER M.-C., VAN CUTSEM O., KÜSTNER U., KROLL F., SERGYSELS R., MOMMEN P., KLASTERSKY Y. for the European Lung Cancer Working A randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small cell cancer. J. Clin. Oncol. 1996, 14 :2337-2344. BORGES M., SCULIERS J.-P., PAESMANS M., LIBERT P., BUREAU G., DABOUIS L., THIRIAUX J., MICHEL J., VAN CUTSEM O., SCHMERBER J., GINER V., BERCHIER M.-C., SERGYSELS R., MOMMEN P., KLASTERSKY J. for the European Lung Cancer Working Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC) Lung Cancer 1996, 16 :21-33 PAESMANS M., SCULIER J.-P., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J., VAN CUTSEM O., SERGYSELS R., MOMMEN P and KLASTERSKY J. for the European Lung Cancer Working Response to chemotherapy has a discriminant value on the distribution of further survival for patients with advanced non small cell lung cancer : a ten experience of the European lung Cancer Working Eur. J. Cancer 1997, 33 :2326-2332. SCULIER J.-P., PAESMANS M., NINANE V., GINER V., BUREAU G., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., VAN HOUTTE P., KLASTERSKY J., the European Lung Cancer Working Les facteurs pronostiques des cancers bronchiques non à petites cellules au stade avancé : l expérience de l European Lung Cancer Working Rev.. Mal. Resp. 1997, 14 :445-449. PAESMANS M., SCULIER J.-P., LECOMPTE J., THIRIAUX J., LIBERT P., SERGYSELS R., BUREAU G., DABOUIS G., VAN CUTSEM O., MOMMEN P., NINANE V., KLASTERSKY J, for the European Lung Cancer Working Prognostic factors for patients with small cell lung cancer : long-term experience of the European Lung Cance Working In «Cancers bronchopulmonaires» (MILLERON B., DEPIERE A.), ARNETTE, VELIZY- VILLACOUBLAY, 1998, pp 239-247. SCULIER J.-P., PAESMANS M., NINANE V., GINER V., BUREAU G., LAFITTE J.-J. BAUMOHL J., THIRIAUX J., CAN CUTSEM O., RECLOUX P., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., VAN HOUTTE P., KLASTERSKY J., the European Lung Cancer Working
Evaluation of the TN sub-staging in patients with initially unresectable stage III non small cell lung cancer treated by induction chemotherapy. Lung cancer, 1998, 22 : 201-203 SCULIER J.-P., PAESMANS M., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BUREAU G., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., BOSSCHAERTS T., BERGHMANS T., VAN HOUTTE P., NINANE V., KLASTERSKY J. - the European Lung Cancer Working A randomised phase III trial comparing further chemotherapy to chest irradiation in objectively responding patients with initially unresectable locoregional non-small cell lung cancer treated by induction chemotherapy. Annals of Oncology. 1999 10 : 295-303. SCULIER J.-P., PAESMANS M., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BUREAU G., BERCHIER M.-C., ZACHARIAS C., MOMMEN P., BOSSCHAERTS T., BERGHMANS T., VAN HOUTTE P., NINANE V., KLASTERSKY J. - the European Lung Cancer Working Prognostic factors analysis for response to chemotherapy and survival in a prospective cohort of patients with unresectable locoregional non small cell lung cancer initially treated by induction chemotherapy. Rev. Oncologia 1999, 1, 92-100. PAESMANS M., SCULIER J.-P., LECOMTE J., THIRIAUX J., LIBERT P., SERGYSELS R., BUREAU G., DABOUIS G., VAN CUTSEM O., MOMMEN P., NINANE V., KLASTERSKY J. for the European Lung Cancer Working Prognostic factors for pataients with small cell lung cancer : analysis of a serie of 763 patients included in 4 consecutive pospective trials and with a minimum follow-up of 75 years. Cancer 2000, 89 : 523-533 SCULIER J.-P., PAESMANS M., LECOMTE J., VAN CUTSEM O., LAFITTE J.-J., BERGHMANS T., KOUMAKIS G., FLORIN M.-C., THIRIAUX J., MICHEL J., GINER V., BERCHIER M.-C., MOMMEN P., NINANE V., KLASTERSKY J. for the European Lung Cancer Working A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer 2001, 88 : 1444-1451. SCULIER J.-P., BERGHMANS T, LAFITTE J.-J., RICHEZ M., RECLOUX P., VAN CUTSEM O., NINANE V., MOMMEN P., PAESMANS M., KLASTERSKY J. for the European Lung Cancer Working A phase III study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung cancer, 2002 37 : 73-77.
SCULIER J.-P, LAFITTE J.-J., LECOMTE J., BERGHMANS T., THIRIAUX J., VAN CUTSEM O., EFREMIDIS A., NINANE V., PAESMANS M., MOMMEN P., KLASTERSKY for the European Lung Cancer Working A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Annals of Oncology, 2002, 13-1454-1459